<VariationArchive RecordType="classified" VariationID="804063" VariationName="NM_000061.3(BTK):c.1784dup (p.Met596fs)" VariationType="Duplication" Accession="VCV000804063" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2020-01-11" MostRecentSubmission="2020-01-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="792100" VariationID="804063">
      <GeneList>
        <Gene Symbol="BTK" FullName="Bruton tyrosine kinase" GeneID="695" HGNC_ID="HGNC:1133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101349450" stop="101390796" display_start="101349450" display_stop="101390796" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100604434" stop="100641211" display_start="100604434" display_stop="100641211" Strand="-" />
          </Location>
          <OMIM>300300</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000061.3(BTK):c.1784dup (p.Met596fs)</Name>
      <CanonicalSPDI>NC_000023.11:101353317:TT:TTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100608305" stop="100608306" display_start="100608305" display_stop="100608306" variantLength="1" positionVCF="100608305" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101353317" stop="101353318" display_start="101353317" display_stop="101353318" variantLength="1" positionVCF="101353317" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
      </Location>
      <ProteinChange>M630fs</ProteinChange>
      <ProteinChange>M596fs</ProteinChange>
      <ProteinChange>M420fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_128" sequenceAccession="LRG_128">
            <Expression>LRG_128:g.37907dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100608307dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100608307dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101353319dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101353319dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009616.1" sequenceAccession="NG_009616" sequenceVersion="1" change="g.37907dup">
            <Expression>NG_009616.1:g.37907dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011734.1" sequenceAccession="NG_011734" sequenceVersion="1" change="g.652dup">
            <Expression>NG_011734.1:g.652dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000061.3" sequenceAccession="NM_000061" sequenceVersion="3" change="c.1784dup" MANESelect="true">
            <Expression>NM_000061.3:c.1784dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000052.1" sequenceAccession="NP_000052" sequenceVersion="1" change="p.Met596fs">
            <Expression>NP_000052.1:p.Met596fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287344.2" sequenceAccession="NM_001287344" sequenceVersion="2" change="c.1886dup">
            <Expression>NM_001287344.2:c.1886dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274273.1" sequenceAccession="NP_001274273" sequenceVersion="1" change="p.Met630fs">
            <Expression>NP_001274273.1:p.Met630fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287345.2" sequenceAccession="NM_001287345" sequenceVersion="2" change="c.1256dup">
            <Expression>NM_001287345.2:c.1256dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274274.1" sequenceAccession="NP_001274274" sequenceVersion="1" change="p.Met420fs">
            <Expression>NP_001274274.1:p.Met420fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1603001771" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000061.3(BTK):c.1784dup (p.Met596fs) AND X-linked agammaglobulinemia" Accession="RCV000990915" Version="1">
        <ClassifiedConditionList TraitSetID="3110">
          <ClassifiedCondition DB="MedGen" ID="C0221026">X-linked agammaglobulinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-05-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-05-28" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-01-11" MostRecentSubmission="2020-01-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="3110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="39" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Bruton-type agammaglobulinemia</ElementValue>
                <XRef ID="MONDO:0010421" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, Bruton tyrosine kinase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, BTK</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BTK-deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked agammaglobulinemia</ElementValue>
                <XRef ID="X-linked+agammaglobulinemia/7543" DB="Genetic Alliance" />
                <XRef ID="65880007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton's agammaglobulinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">XLA</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AGMX1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IMD1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</Attribute>
                <XRef ID="NBK1453" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1033" />
                <XRef ID="1033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301626</ID>
                <ID Source="BookShelf">NBK1453</ID>
              </Citation>
              <XRef ID="229717" DB="Orphanet" />
              <XRef ID="47" DB="Orphanet" />
              <XRef ID="C0221026" DB="MedGen" />
              <XRef ID="MONDO:0010421" DB="MONDO" />
              <XRef Type="MIM" ID="300755" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2247771" SubmissionDate="2019-10-22" DateLastUpdated="2020-01-11" DateCreated="2020-01-11">
        <ClinVarSubmissionID localKey="NC_000023.10:g.100608305_100608306insT|OMIM:300755" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001141968" DateUpdated="2020-01-11" DateCreated="2020-01-11" Type="SCV" Version="1" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2017</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/chhjzatu/mendelics_assertion_criteria_2017.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BTK" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.100608305_100608306insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="300755" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_020</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2247771" TraitType="Disease" MappingType="XRef" MappingValue="300755" MappingRef="OMIM">
        <MedGen CUI="C0221026" Name="X-linked agammaglobulinemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

